Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition

PARP inhibitor monotherapies are effective to treat patients with breast, ovary, prostate, and pancreatic cancer with BRCA1 mutations, but not to the much more frequent BRCA wild-type cancers. Searching for strategies that would extend the use of PARP inhibitors to BRCA1-proficient tumors, we found...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Res
Autors principals: Luo, Man-Li, Zheng, Fang, Chen, Wenying, Liang, Zhi-Mei, Chandramouly, Gurushankar, Tan, Jianan, Willis, Nicholas A., Chen, Chun-Hau, Taveira, Mateus de Oliveira, Zhou, Xiao Zhen, Lu, Kun Ping, Scully, Ralph, Wulf, Gerburg M., Hu, Hai
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755124/
https://ncbi.nlm.nih.gov/pubmed/32193285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-2739
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars